Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi


  • Dong Hoon Suh
  • Yong Sang SongEmail author
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101577


Historical Background

Although the Ebers papyrus from ancient Egypt (1850 BC), the oldest preserved medical text, includes the first record of the use of plant remedies from the bark of poplar trees for the treatment of pain and fever, it was not until 1800s that the antipyretic and analgesic effects of willow bark was known to be originated from the active component, salicin. Later on, Kolbe and Lautemann developed a highly efficient method for the synthesis of salicylic acid from phenol. In 1897, “aspirin” was developed by Bayer Company and distributed in the general population as an antiseptic and antipyretic. Despite the wide use of nonsteroidal anti-inflammatory drug (NSAID) over the last century, the mechanism of action was not fully understood until 1971, when Vane, an awardee of Nobel Prize in physiology and medicine in 1982, showed that NSAIDs inhibited the enzyme...
This is a preview of subscription content, log in to check access.


  1. Bertolini A, Ottani A, Sandrini M. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Curr Med Chem. 2002;9:1033–43.PubMedCrossRefGoogle Scholar
  2. Blobaum AL, Marnett LJ. Structural and functional basis of cyclooxygenase inhibition. J Med Chem. 2007;50:1425–41.PubMedCrossRefGoogle Scholar
  3. Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol. 2001;127:411–7.PubMedCrossRefGoogle Scholar
  4. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063–73.PubMedCrossRefGoogle Scholar
  5. Jo H, Kang S, Kim JW, Kang GH, Park NH, Song YS, et al. Hypermethylation of the COX-2 gene is a potential prognostic marker for cervical cancer. J Obstet Gynaecol Res. 2007;33:236–41.PubMedCrossRefGoogle Scholar
  6. Kim EH, Na HK, Kim DH, Park SA, Kim HN, Song NY, et al. 15-Deoxy-Delta12,14-prostaglandin J2 induces COX-2 expression through Akt-driven AP-1 activation in human breast cancer cells: a potential role of ROS. Carcinogenesis. 2008;29:688–95.PubMedCrossRefGoogle Scholar
  7. Kim SH, Oh JM, No JH, Bang YJ, Juhnn YS, Song YS. Involvement of NF-kappaB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein. Carcinogenesis. 2009;30:753–7.PubMedCrossRefGoogle Scholar
  8. Kim HS, Kim T, Kim MK, Suh DH, Chung HH, Song YS. Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia. J Cancer Prev. 2013;18:123–34.PubMedPubMedCentralCrossRefGoogle Scholar
  9. Lee JY, Myung SK, Song YS. Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: a meta-analysis of observational studies. Gynecol Oncol. 2013;129:613–9.PubMedCrossRefGoogle Scholar
  10. Liu Y, Sun H, Hu M, Zhang Y, Chen S, Tighe S, et al. The role of cyclooxygenase-2 in colorectal carcinogenesis. Clin Colorectal Cancer. 2016.  https://doi.org/10.1016/j.clcc.2016.09.012.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Miao XP, Li JS, Ouyang Q, Hu RW, Zhang Y, Li HY. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease. Cochrane Database Syst Rev. 2014;CD007744.Google Scholar
  12. Miyamoto T, Ogino N, Yamamoto S, Hayaishi O. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem. 1976;251:2629–36.PubMedPubMedCentralGoogle Scholar
  13. Nakanishi M, Rosenberg DW. Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol. 2013;35:123–37.PubMedCrossRefGoogle Scholar
  14. Nandakishore R, Yalavarthi PR, Kiran YR, Rajapranathi M. Selective cyclooxygenase inhibitors: current status. Curr Drug Discov Technol. 2014;11:127–32.PubMedCrossRefGoogle Scholar
  15. Qiao L, Li X. Role of chronic inflammation in cancers of the gastrointestinal system and the liver: where we are now. Cancer Lett. 2014;345:150–2.PubMedCrossRefGoogle Scholar
  16. Surh YJ, Kundu JK. Cancer preventive phytochemicals as speed breakers in inflammatory signaling involved in aberrant COX-2 expression. Curr Cancer Drug Targets. 2007;7:447–58.PubMedCrossRefGoogle Scholar
  17. Thompson PA, Ashbeck EL, Roe DJ, Fales L, Buckmeier J, Wang F, et al. Celecoxib for the prevention of colorectal adenomas: results of a suspended randomized controlled trial. J Natl Cancer Inst. 2016;108.Google Scholar
  18. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232–5.PubMedCrossRefGoogle Scholar
  19. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110:255–8.PubMedCrossRefGoogle Scholar
  20. Yu T, Lao X, Zheng H. Influencing COX-2 activity by COX related pathways in inflammation and cancer. Mini Rev Med Chem. 2016;16:1230–43.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologySeoul National University Bundang HospitalSeongnam-siKorea
  2. 2.Division of Gynecologic Oncology, Department of Obstetrics and GynecologySeoul National University College of MedicineJongnoguKorea